Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sabby Management Joins Alpha Capital Anstalt in DARA Biosciences With 8.3% Stake

Sabby Management, Dara Biosciences: In a new 13G filing just reported to the SEC, Hal Mintz’s Sabby Management reported an 8.3% stake in DARA Biosciences Inc (NASDAQ:DARA) stock. Due to the nature of the disclosure, Sabby is here as a passive investor, much as Alpha Capital Anstalt reported yesterday. At market close, Alpha reported a slightly smaller 7.6% stake in Dara.

Dara Biosciences

A couple of days earlier, Dara Biosciences announced it is entering into a Securities Purchase Agreement with several institutional investors, in which the company intends to sell 5.1 million shares in a direct offering. The price of the offering is set at $0.50 per share with gross proceeds amounting to almost $2.6 million, Dara Biosciences said in a statement.

Disclosure: none

Recommended Reading:

Hirzel Capital Just Bought More Hawaiian Holdings Stock at $7.40/Share

Solus Alternative Asset Management Sells Some YRC Worldwide

How Warren Buffett’s ‘LeBron James Analogy’ Could Make You A Fortune